Vireo Growth Inc. Exercises Option to Purchase New York Facility from Innovative Industrial Properties
Cannabis Roll‑Up Vireo Growth Takes On 15% Seller Financing to Buy New York Facility as Dilution and Debt Pile Mount
Vireo Growth Inc., through a subsidiary, exercised an option to purchase a 389,000 sq. ft. cannabis cultivation and production facility in Perth, New York, from Innovative Industrial Properties (IIP‑NY 2 LLC). The purchase price was US$88.5 million, funded by: - A US$49 million seller note from IIP at 15% annual interest, maturing May 2027 with two one‑year extension options, secured by a first priority mortgage on the property and guaranteed by Vireo. - A US$41 million loan from Chicago Atlantic Financial Services, secured by a second priority mortgage and guaranteed by Vireo Health, Inc. The facility was previously leased from IIP; the acquisition consolidates ownership of a key operational asset.
The acquisition itself is not new – it exercises a previously disclosed purchase option, making it expected. The material element lies in the financing terms. A 15% seller note on US$49 million is punitive by any standard and signals that traditional, lower‑cost capital is unavailable or that Vireo’s balance sheet is already stretched. The US$41 million second‑lien loan adds further leverage. Combined annual interest on the seller note alone (~US$7.35 million) will absorb a meaningful portion of Q1 2026 Adjusted EBITDA (US$32.7 million).
In the context of historical news, Vireo has been on an acquisition spree (Schwazze, Eaze, Hawthorne, PharmaCann, FLUENT, now Bridgewell), all funded by massive equity issuance and increasing debt. The share count has ballooned to an estimated 1.5 billion, and the stock has eroded from $1.05 to $0.61. The New York deal, while routine in nature, highlights escalating financial risk: high‑cost debt combined with aggressive dilution undermines per‑share value and could strain liquidity despite the reported US$137.8 million cash reserve. No game‑changing improvement is announced; rather, the optics are of a company forced to accept unfavorable terms to finalize an expected transaction.
Vireo Growth Inc. is a U.S. multi‑state cannabis operator that has rapidly expanded through aggressive M&A. Its footprint now spans at least 10 states with over 160 dispensaries and ~800,000 sq. ft. of cultivation/manufacturing space. The company does not have a single flagship project; rather, it is executing a roll‑up strategy, acquiring distressed or undervalued assets (Schwazze, Eaze, PharmaCann assets, FLUENT, etc.). The recently purchased New York facility is an important cultivation hub, but the portfolio is diverse.